Loading...
•
Jun 30, 2020
Zentalis Q2 2020 Earnings Report
Zentalis reported financial results for the second quarter ended June 30, 2020, and highlighted recent corporate accomplishments.
Key Takeaways
Zentalis Pharmaceuticals reported a net loss of $27.3 million for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $233.2 million as of June 30, 2020, which, along with proceeds from a follow-on offering, is expected to fund operations into 2023. The company also completed its IPO, raised additional capital, and entered into strategic collaborations.
Closed initial public offering (IPO) of common stock, raising gross proceeds of ~$190.0 million.
Raised an additional ~$144.4 million in gross proceeds from recent follow-on offering.
Completed a $20.0 million Series A financing to establish Zentera Therapeutics, a majority- owned Chinese joint venture.
Entered into strategic collaborations with Eli Lilly and Tavros Therapeutics to further advance oncology pipeline
Forward Guidance
Zentalis expects that the Company’s existing cash, cash equivalents and marketable securities, together with the net proceeds of approximately $135.0 million from the follow-on offering, will enable the Company to fund its operating expenses and capital expenditure requirements into 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...